1. Home
  2. SDEV vs NSPR Comparison

SDEV vs NSPR Comparison

Compare SDEV & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$1.16

Market Cap

33.1M

Sector

Health Care

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.65

Market Cap

33.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDEV
NSPR
Founded
N/A
2005
Country
United States
United States
Employees
4
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1M
33.7M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
SDEV
NSPR
Price
$1.16
$0.65
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
169.3K
49.7K
Earning Date
N/A
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.63
52 Week High
$1.60
$2.70

Technical Indicators

Market Signals
Indicator
SDEV
NSPR
Relative Strength Index (RSI) 49.57 30.84
Support Level $1.05 $0.63
Resistance Level $1.58 $0.72
Average True Range (ATR) 0.08 0.03
MACD -0.01 0.00
Stochastic Oscillator 32.68 0.00

Price Performance

Historical Comparison
SDEV
NSPR

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: